Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-13 5:17 pm Purchase | 13G | Xeris Biopharma Holdings Inc. XERS | VANGUARD GROUP INC | 7,086,345 5.130% | 7,086,345 (New Position) | View |
| 2024-02-13 4:34 pm Sale | 13G | Xeris Biopharma Holdings Inc. XERS | Stonepine Capital Management LLC | 5,937,000 4.300% | -5,258,189 (-46.97%) | View |
| 2024-01-26 4:23 pm Purchase | 13G | Xeris Biopharma Holdings Inc. XERS | BlackRock Inc. BLK | 10,011,391 7.200% | 1,435,178 (+16.73%) | View |
| 2023-02-14 12:15 pm Sale | 13G | Xeris Biopharma Holdings Inc. XERS | CAXTON CORP | 5,973,324 4.400% | -1,856,358 (-23.71%) | View |
| 2023-02-13 10:57 am Purchase | 13G | Xeris Biopharma Holdings Inc. XERS | Stonepine Capital Management LLC | 11,195,189 8.200% | 4,704,090 (+72.47%) | View |
| 2023-02-10 09:04 am Purchase | 13G | Xeris Biopharma Holdings Inc. XERS | BlackRock Inc. BLK | 8,576,213 6.300% | 8,576,213 (New Position) | View |
| 2022-02-11 4:20 pm Purchase | 13G | Xeris Biopharma Holdings Inc. XERS | Flynn James E | 5,882,353 4.500% | 5,882,353 (New Position) | View |
| 2022-01-13 6:13 pm Purchase | 13G | Xeris Biopharma Holdings Inc. XERS | Stonepine Capital Management LLC | 6,491,099 5.200% | 6,491,099 (New Position) | View |
| 2022-01-05 12:38 pm Purchase | 13G | Xeris Biopharma Holdings Inc. XERS | CAXTON CORP | 7,829,682 5.700% | 7,829,682 (New Position) | View |